Addition of Ramucirumab or Merestinib to Standard First-Line Chemotherapy for Locally Advanced or Metastatic Biliary Tract Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
Lancet Oncol 2021 Oct 01;22(10)1468-1482, JW Valle, A Vogel, CS Denlinger, AR He, LY Bai, R Orlova, E Van Cutsem, J Adeva, LT Chen, R Obermannova, TJ Ettrich, JS Chen, H Wasan, AC Girvan, W Zhang, J Liu, C Tang, PJ Ebert, A Aggarwal, SC McNeely, BA Moser, JM Oliveira, R Carlesi, RA Walgren, DY OhFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.